News and Events

OEM Partners to Drive Bio‑Banking Growth

Investment Highlights

  • Bluechiip Limited's (BCT) technology has the potential to displace the current incumbents in the chain‑of‑custody accessories segment of the bio‑banking industry and potentially other logistic processes.
  • The shift to an Original Equipment Manufacturer (OEM) partner model is accelerating with the Genea Biomedx License and Supply agreement being signed in December 2015 and talks currently being held with an extensive pipeline of additional partners.
  • BCT may be able to take advantage of its disruptive technology in the growing bio‑banking industry and leverage off its OEM partners to carve out a significant market share for itself.
  • Given the Company's promising long term prospects and positive news flow expected in the short term, namely the signing of additional OEM partners, we feel BCT's depressed share price is unjustified and should rerate.
  • We maintain our Speculative Buy rating, but do highlight the need for a further capital raising in the near future.

FULL ARTICLE

Jon Scholtz
Analyst

D: +61 8 9225 2836 | E: jscholtz@psl.com.au | W: www.psl.com.au
Patersons Securities Limited AFSL No. 239 052
Level 23, Exchange Tower, 2 The Esplanade PERTH WA 6000
GPO Box W2024, Perth, WA 6846

« Back

bluechiip Limited issued this content on 11 February 2016 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 11 February 2016 03:01:24 UTC

Original Document: http://www.bluechiip.com/2016/02/buy/